Biosimilar Regulatory solution center

  1. 2018 Biosimilar Triumphs And Tribulations: How Have Market Expectations Evolved?
    12/11/2018

    In the first part of a three-part “Ask The Board” series, members of the editorial board share what left them feeling the most heartened or concerned in 2018 and what must take center stage as we head into 2019.

  2. How Can The FDA Take Ownership Of Biosimilars In 2019?
    12/6/2018

    In lieu of the slow development of the U.S. biosimilar market, the FDA has stepped up to determine how it can improve biosimilar education, regulation, and market access. As many of the industry comments to the Biosimilar Action Plan revealed, this will require the FDA to continue broadening its purview and refining the regulatory pathway by implementing several specific actions.

  3. The Biosimilar Market Is Evolving: How Can Education Strategies Follow Suit?
    11/30/2018

    In this article, I’ll discuss the importance of one commonly overlooked expert and highlight one recent educational initiative that exemplifies current needs in biosimilar communication strategies.  

  4. Express Scripts New Flex Formulary: Biosimilar Friend Or Foe?
    11/27/2018

    Though it’s much too early to say for sure, we will need to watch how this formulary impacts the brand vs. biosimilar landscape, and, in turn, the performance of biosimilars in the pharmacy reimbursement space.

  5. How Will Trump’s New FTC/DOJ Reporting Requirements Impact Biosimilars?
    11/13/2018

    On Oct. 10, 2018, President Trump signed into law the Patient Right to Know Drug Prices Act, which, among other things, requires that certain biosimilar applicants and reference product sponsors involved in patent disputes file their settlement agreements with the FTC and the DOJ. This article summarizes the key provisions of the new law and discusses its limitations.

  6. If Four-Letter Suffixes Aren’t Used In Biosimilar Tracking, What Use Are They?
    11/6/2018

    The implementation of the Biologics Price Competition and Innovation Act1 (BPCIA) raised a number of critical issues for manufacturers, payers, and prescribers. These include the big-picture questions of extrapolation of indications, interchangeability, and a radical new approach to evaluating the comparability of these drugs to their reference biologics, as well as approving them.

  7. A Biosimilar Manufacturer’s Sword & Shield Against Doctrine Of Equivalents Claims
    10/23/2018

    While biosimilar manufacturers face many unique challenges in patent litigation, one of the most common is an infringement action brought under the doctrine of equivalents (DOE). DOE is a principle where a party sues for infringing on the general spirit of the patent, rather than on the specific content of its claims.

  8. Biosimilar Policies To Watch As We Approach 2019
    10/18/2018

    I reached out to Biosimilar Development editorial board member Molly Burich of Boehringer Ingelheim for her input on the policies she expects could have the largest positive or negative impact on biosimilars, as well as what progress has been made on the policy front.

  9. The Current State Of U.S. Biosimilar Policies — An Overview
    10/17/2018

    With the continued policy dialogue on how rising drug costs impact patient access, the theoretical cost savings that biosimilars may offer is intriguing to many policymakers as well as those in the industry. 

  10. A Possible “Humirageddon:” Perspectives On The EU Biosimilar Launch
    10/16/2018

    In the wake of the arrival of Humira biosimilars in the EU, Jorge Santos da Silva and Jennifer Heller of McKinsey & Company share several critical pricing and market considerations for companies as this highly anticipated product finally becomes available to patients.